ArticleBrain communications2023
Predictive blood biomarkers and brain changes associated with age-related cognitive decline.
Article in Brain communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- The impact of exercise on blood-based biomarkers of Alzheimer's disease in cognitively unimpaired older adults.GeroScience · 2024Trial
- Blood Biomarkers of Alzheimer Disease and Rates of Global and Domain-Specific Cognitive Decline.JAMA network open · 2026Article
- Beyond amyloid: Contributions of neuroinflammation, cerebrovascular disease, and neurodegeneration to memory impairment in the oldest-old, the LifeAfter90 Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains.medRxiv : the preprint server for health sciences · 2026Article
- Timing matters: early administration of a high-affinity antibody targeting the tau repeat domain prevents aggregation in a mouse tauopathy model.Alzheimer's research & therapy · 2026Article
- Non-compacted, PET-insensitive amyloid states increase after systemic inflammation and predict neuritic damage across Aβ pathology models and Alzheimer patients.Research square · 2026Article
- AD-related plasma biomarkers in centenarians: links to cognition and neuropathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Distinctive volumetric associations between plasma p-tau181 and hippocampal formation structures across the Alzheimer's disease continuum.Journal of Alzheimer's disease : JAD · 2025Article
- Neocortical tau propagation is a mediator of clinical heterogeneity in Alzheimer's disease.Molecular psychiatry · 2025Article
- Blood biomarker profiles in young-onset neurocognitive disorders: A cohort study.The Australian and New Zealand journal of psychiatry · 2025Article
- Phosphorylated Tau at T181 accumulates in the serum of hibernating Syrian hamsters and rapidly disappears after arousal.Scientific reports · 2024Article
- Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease.Translational neurodegeneration · 2024Review
- Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients.Alzheimer's research & therapy · 2024Article
- Associations Between Blood-Based Biomarkers and Cognitive and Functional Trajectories Among Participants of the MEMENTO Cohort.Neurology · 2024Article
- Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review.Biomolecules · 2024Review
- Towards early diagnosis of Alzheimer's disease: advances in immune-related blood biomarkers and computational approaches.Frontiers in immunology · 2024Review
- Human astrocytes and microglia show augmented ingestion of synapses in Alzheimer's disease via MFG-E8.Cell reports. Medicine · 2023Article
- Is phosphorylated tau a good biomarker of synapse pathology in Alzheimer's disease?Brain communications · 2023Article
- Identifying populations with faster cognitive decline using blood-based biomarkers.Alzheimer's & dementia (New York, N. Y.)Article
- Predicting brain health in community-dwelling elderly populations by integrating Gaussian mixture model and plasma biomarkers.Journal of Alzheimer's disease reportsArticle
Corrections and comments
- Commented on by
- Comment on
Authors and funding
13 authors at 4 institutions in 4 countries.
Funding
Abstract
Growing evidence supports the use of plasma levels of tau phosphorylated at threonine 181, amyloid-β, neurofilament light and glial fibrillary acidic protein as promising biomarkers for Alzheimer's disease. While these blood biomarkers are promising for distinguishing people with Alzheimer's disease from healthy controls, their predictive validity for age-related cognitive decline without dementia remains unclear. Further, while tau phosphorylated at threonine 181 is a promising biomarker, the distribution of this phospho-epitope of tau in the brain is unknown. Here, we tested whether plasma levels of tau phosphorylated at threonine 181, amyloid-β, neurofilament light and fibrillary acidic protein predict cognitive decline between ages 72 and 82 in 195 participants in the Lothian birth cohorts 1936 study of cognitive ageing. We further examined post-mortem brain samples from temporal cortex to determine the distribution of tau phosphorylated at threonine 181 in the brain. Several forms of tau phosphorylated at threonine 181 have been shown to contribute to synapse degeneration in Alzheimer's disease, which correlates closely with cognitive decline in this form of dementia, but to date, there have not been investigations of whether tau phosphorylated at threonine 181 is found in synapses in Alzheimer's disease or healthy ageing brain. It was also previously unclear whether tau phosphorylated at threonine 181 accumulated in dystrophic neurites around plaques, which could contribute to tau leakage to the periphery due to impaired membrane integrity in dystrophies. Brain homogenate and biochemically enriched synaptic fractions were examined with western blot to examine tau phosphorylated at threonine 181 levels between groups (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.